Novartis AG

NVS Healthcare Drug Manufacturers General

Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024.

Revenue
+4.67%
EPS
−69.1%
Free cash flow
−17.8%
Total debt
+53.9%

Quarter to September 2026, against a year earlier

162.04 2.94 −1.78%
Market cap
$296.4B
P/E
30.9×
Fwd P/E
23.2×
Dividend yield
2.93%
F-score
8/9
Altman Z
4.13
Beneish M
−2.49
Dividend safety
66/100

Novartis AG (NVS) EV/FCF

Alert me on EV/FCF

As of 5 November 2026, Novartis AG (NVS) trades at a EV/FCF of 24.4×. Over the past ten years it has ranged from 12.8× (October 2023) to 24.8× (November 2026); the current reading is higher than 100% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 18.8× 23.32%
FY2024 15.2× (3.90%)
FY2023 15.8× (3.34%)
FY2022 16.4× 12.40%
FY2021 14.6× (27.73%)
FY2020 20.2× 17.82%
FY2019 17.1× 2.89%
FY2018 16.6× (16.49%)
FY2017 19.9× 4.34%
FY2016 19.1× (12.49%)

Quarterly newest first

Period EV/FCF Change
Sep 2026 21.8× (2.31%)
Jun 2026 22.3× 8.93%
Mar 2026 20.4× 8.97%
Dec 2025 18.8× 20.73%
43 more quarters

Against its own ten years

Low 12.8× High 24.8×
Ten-year median 18.0×
Current reading's percentile 100

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on NVS